Skip links
InSymbiosis is now part of Camargo

On June 12, 2019, InSymbiosis was acquired by Camargo. The solutions now available through Camargo Research Group are the same as those previously offered through InSymbiosis.

In addition to the nonclinical development support you have come to know through InSymbiosis, together as Camargo, we deliver more. Our portfolio accelerates your path to market through integrated solutions including Development and Regulatory Strategy, CMC, and Clinical & PK. Explore our comprehensive solutions over on the Camargo website.

For more information about the acquisition, read our press release.

For Sponsors

Drive Program Success from the Start

Our experienced team of drug development experts is committed to helping you reach critical decisions faster. With your research goals in mind, we provide study design, CRO selection and program management solutions to execute a full range of GLP and non-GLP preclinical evaluation studies and advance your program to first-in-human studies.


  • ADME
  • Animal efficacy
  • Bioanalysis
  • Candidate selection
  • Discovery pharmacokinetics (PK)
  • Dose formulation analysis
  • Drug characterization
  • hERG and genotoxicity


  • IND and NDA enabling programs
  • Bioanalysis
  • Carcinogenicity
  • Developmental and reproductive studies
  • Dose range finding and repeated-dose studies
  • Genetic toxicology
  • Pathology
  • Pharmacokinetics (PK)
  • Safety pharmacology
  • Specialized studies

Advance Seamlessly into the Clinic

Transition into the clinic and set your sights on moving to and through proof of concept with CMC and early clinical support.


  • Formulation development
  • Full process development and manufacturing
  • Packaging and distribution
  • Stability studies


  • Bioequivalence
  • Food effects
  • Phase 1-2
  • Single ascending dose and multiple ascending dose (SAD & MAD)
Let’s Get Started


Our team brings diverse scientific and drug development expertise in areas including ADME/PK, bioanalysis, CMC, pharmacology and toxicology. We leverage Camargo Quality Management support capabilities to stay at the forefront of quality and compliance standards. The compounds and studies we support include:


  • Antibodies
  • Drug conjugates
  • Oligonucleotide
  • Peptides
  • Proteins
  • Small molecules
  • Vaccines


  • Acute to chronic
  • All major indications
  • All major routes of administration
  • All major species including NHPs
  • Non-GLP and GLP